Brief: SynAct Pharma Q4 Sales SEK 0
23/02/2024 06:50
Feb 23 (Reuters) - SynAct Pharma Q4 cash flow from operating activities SEK -20.395 million. * Q4 adjusted EPS SEK -2.58 * Q4 net income SEK -90.543 million * Q4 operating expenses SEK 91.062 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026